We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced that the European Commission (EC) has approved an expanded indication for its meningococcal vaccine, Nimenrix.
We note that Pfizer has outperformed the Zacks classified Large Cap Pharmaceuticals industry year to date. In fact, the company has gained 1.8% so far this year, compared to a drop of 6.0% for the industry.
Coming back to the news, Nimenrix was approved for active immunization against invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135, and Y (MenACWY) in infants as young as six weeks of age. The vaccine was earlier approved for the same indication in individuals aged six weeks and above.
We note that Pfizer’s meningococcal vaccines portfolio includes vaccines that help fight against the five most common disease-causing serogroups – A, C, W-135, Y, and B (approvals varying by country).
Note that Pfizer has been focused on deploying increased resources for the development of treatments in the fields of oncology, cardiology, metabolic disorders, neuroscience, pain, rare diseases, immunology, inflammation and vaccines as well as immuno-oncology.
Concurrently, Pfizer announced encouraging results from a sub-analysis on the phase III trial, PALOMA- 2, on Ibrance, in combination with Femara, as first-line therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer. The study is being conducted among Asian patients.
The results showed that the combination of Ibrance and Femara significantly extended progression-free survival (PFS) by more than 11 months, compared with Femara plus placebo, along with demonstrating that the median PFS exceeded two years in these patients.
Ibrance is currently approved in many Asian countries, in combination with Femara, for the treatment of postmenopausal women with ER+, HER2- advanced breast cancer as initial endocrine-based therapy for their metastatic disease. However, competition is stiff in the breast cancer market.
We remind investors that Roche (RHHBY - Free Report) dominates the breast cancer space with strong demand for its HER2 franchise drugs. The HER2 franchise includes Herceptin, Perjeta and Kadcyla.
Heska’s earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301.64%. Its share price has increased 94.1% year to date.
Vanda’s loss estimates for 2016 narrowed from 62 cents to 52 cents, while its earnings estimates for 2017 increased from 13 cents to 22 cents over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price has surged almost 83% year to date.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU
Pfizer Inc. (PFE - Free Report) announced that the European Commission (EC) has approved an expanded indication for its meningococcal vaccine, Nimenrix.
We note that Pfizer has outperformed the Zacks classified Large Cap Pharmaceuticals industry year to date. In fact, the company has gained 1.8% so far this year, compared to a drop of 6.0% for the industry.
Coming back to the news, Nimenrix was approved for active immunization against invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135, and Y (MenACWY) in infants as young as six weeks of age. The vaccine was earlier approved for the same indication in individuals aged six weeks and above.
We note that Pfizer’s meningococcal vaccines portfolio includes vaccines that help fight against the five most common disease-causing serogroups – A, C, W-135, Y, and B (approvals varying by country).
Note that Pfizer has been focused on deploying increased resources for the development of treatments in the fields of oncology, cardiology, metabolic disorders, neuroscience, pain, rare diseases, immunology, inflammation and vaccines as well as immuno-oncology.
Concurrently, Pfizer announced encouraging results from a sub-analysis on the phase III trial, PALOMA- 2, on Ibrance, in combination with Femara, as first-line therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+, HER2-) metastatic breast cancer. The study is being conducted among Asian patients.
The results showed that the combination of Ibrance and Femara significantly extended progression-free survival (PFS) by more than 11 months, compared with Femara plus placebo, along with demonstrating that the median PFS exceeded two years in these patients.
Ibrance is currently approved in many Asian countries, in combination with Femara, for the treatment of postmenopausal women with ER+, HER2- advanced breast cancer as initial endocrine-based therapy for their metastatic disease. However, competition is stiff in the breast cancer market.
We remind investors that Roche (RHHBY - Free Report) dominates the breast cancer space with strong demand for its HER2 franchise drugs. The HER2 franchise includes Herceptin, Perjeta and Kadcyla.
Pfizer carries a Zacks Rank #3 (Hold).
Key Picks in the Sector
A couple of better-ranked stocks in the health care sector include Heska Corp. , and Vanda Pharmaceuticals (VNDA - Free Report) . Each of these stocks sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.13 to $1.35 for 2016 and from $1.38 to $1.53 for 2017 over the last 60 days. The company posted a positive earnings surprise in all of the four trailing quarters with an average beat of 301.64%. Its share price has increased 94.1% year to date.
Vanda’s loss estimates for 2016 narrowed from 62 cents to 52 cents, while its earnings estimates for 2017 increased from 13 cents to 22 cents over the last 60 days. The company posted a positive earnings surprise in three of the four trailing quarters with an average beat of 56.65%. Its share price has surged almost 83% year to date.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>